

Title (en)
PENTRAXIN I AND PENTRAXIN RECEPTOR, INHIBITORS OF SAID PROTEINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS

Title (de)
PENTRAXIN I UND PENTRAXIN REZEPTOR, DESSEN INHIBITOREN UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

Title (fr)
PENTRAXINE I ET RECEPTEUR DE PENTRAXINE, INHIBITEURS DE CES PROTEINES ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES

Publication
EP 1230356 A2 20020814 (EN)

Application
EP 00979564 A 20001115

Priority
• EP 00979564 A 20001115
• EP 0011302 W 20001115
• EP 99122666 A 19991115

Abstract (en)
[origin: EP1101820A1] Described are nucleic acid sequences encoding the human Pentraxin receptor and related proteins as well as a pharmaceutical composition comprising a therapeutically effective amount of (a) Pentraxin I or the human Pentraxin receptor, (b) a nonfunctional variant of the protein of (a), (c) an antibody to the protein of (a) or (b), (d) a nucleic acid sequence encoding the protein of (a) or (b), (e) an antisense RNA sequence characterized in that it is complementary to an Pentraxin I or human Pentraxin receptor mRNA and can selectively bind to said mRNA, said sequence being capable of inhibiting the synthesis of Pentraxin I or the human Pentraxin receptor, or (f) a ribozyme characterized in that it is complementary to an Pentraxin I or human Pentraxin receptor mRNA and can selectively bind to and cleave said mRNA, thus inhibiting the synthesis of Pentraxin I or the human Pentraxin receptor. Moreover, the use of the above compounds for treating neuronal disorders or providing a neuroprotective effect is described. The above compounds are also useful for detecting a disease associated with a neuronal disorder based on a deregulated expression of the above proteins or the presence of Pentraxin I/human Pentraxin receptor having no or at least reduced biological activity.

IPC 1-7
C12N 15/11

IPC 8 full level
C12N 15/09 (2006.01); **A61K 31/7088** (2006.01); **A61K 38/00** (2006.01); **A61K 38/43** (2006.01); **A61K 39/395** (2006.01); **A61P 25/00** (2006.01); **A61P 25/28** (2006.01); **A61P 35/00** (2006.01); **C07K 14/475** (2006.01); **C07K 14/705** (2006.01); **C07K 14/71** (2006.01); **C07K 16/28** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/10** (2006.01); **C12N 15/11** (2006.01); **C12N 15/18** (2006.01); **C12P 21/02** (2006.01); **C12Q 1/68** (2006.01); **A61K 48/00** (2006.01)

CPC (source: EP)
A61P 25/00 (2017.12); **A61P 25/28** (2017.12); **A61P 35/00** (2017.12); **C07K 14/4756** (2013.01); **C07K 14/71** (2013.01); **A61K 38/00** (2013.01); **A61K 48/00** (2013.01)

Citation (search report)
See references of WO 0136626A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL

DOCDB simple family (publication)
EP 1101820 A1 20010523; AU 1700801 A 20010530; CA 2389662 A1 20010525; EP 1230356 A2 20020814; JP 2003514528 A 20030422; WO 0136626 A2 20010525; WO 0136626 A3 20011018; WO 0136626 A9 20020912

DOCDB simple family (application)
EP 99122666 A 19991115; AU 1700801 A 20001115; CA 2389662 A 20001115; EP 0011302 W 20001115; EP 00979564 A 20001115; JP 2001538505 A 20001115